首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >Convexity Subarachnoid Hemorrhage Soon after Starting a Direct Oral Anticoagulant in 2 Patients with Acute Infarction
【24h】

Convexity Subarachnoid Hemorrhage Soon after Starting a Direct Oral Anticoagulant in 2 Patients with Acute Infarction

机译:在2例急性梗死患者开始直接口服抗凝血剂后,凸性蛛网膜下腔出血不久

获取原文
获取原文并翻译 | 示例
           

摘要

Convexity subarachnoid hemorrhage (cSAH) is typically due to head trauma, but it rarely occurs subsequent to acute ischemic stroke. Direct oral anticoagulants (DOACs) have favorable bleeding profiles as compared with warfarin, and, to our knowledge, no DOAC has been regarded as a causative agent for cSAH. Here, we reported 2 patients with cSAH apparently caused by starting DOAC therapy. No hemorrhage had been evident just prior to treatment initiation, but cSAH occurred so soon after DOAC therapy began. Each of our patients had occlusion or severe stenosis of a major artery due to emboligenic disease, and cSAH occurred in the territory of the affected artery. Reperfusion and dynamic changes in perfusion pressure due may trigger cSAH. Clinicians should remain alert for cSAH when starting DOAC for treatment of embolic ischemic stroke during the acute phase.
机译:凸出性蛛网膜下腔出血(cSAH)通常是由于头部外伤,但很少发生在急性缺血性中风后。与华法林相比,直接口服抗凝剂(DOAC)具有良好的出血情况,而且据我们所知,没有DOAC被视为cSAH的病原体。在这里,我们报告了2例明显由DOAC治疗引起的cSAH患者。在开始治疗前没有明显的出血,但在DOAC治疗开始后很快就发生了cSAH。我们的每位患者都因栓塞性疾病导致大动脉闭塞或严重狭窄,cSAH发生在受影响的动脉区域。再灌注和灌注压的动态变化可能触发cSAH。在急性期开始DOAC治疗栓塞性缺血性中风时,临床医生应保持对cSAH的警惕。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号